General Information of Drug (ID: DMFC41K)

Drug Name
Tafluprost Drug Info
Synonyms Zioptan (TN)
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Approved [1]
Ocular hypertension 9C61.01 Approved [2]
Cross-matching ID
PubChem CID
9868491
ChEBI ID
CHEBI:66899
CAS Number
CAS 209860-87-7
TTD Drug ID
DMFC41K
ACDINA Drug ID
D01455

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [4]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [5]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [6]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [7]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [8]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [9]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [10]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [11]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [12]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Modulator [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7451).
2 Tafluprost FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
5 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
6 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
9 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
10 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
11 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
12 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
13 Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9.